<DOC>
	<DOCNO>NCT01300819</DOCNO>
	<brief_summary>The primary objective study demonstrate Rotigotine improve non-motor symptom compare Placebo subject Parkinson 's Disease .</brief_summary>
	<brief_title>Placebo-controlled Study Patients With Parkinson 's Disease Evaluate Effect Rotigotine Non-motor Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject male female , ≥18 year age Subject idiopathic Parkinson 's disease least 2 follow cardinal sign present : bradykinesia , rest tremor , rigidity postural instability , without know suspected cause Parkinsonism Subject Hoehn Yahr stage score ≤4 Subject total NonMotor Symptoms Scale ( NMSS ) score ≥40 If subject take levodopa ( LDOPA ) , he/she must stable dose LDOPA ( combination benserazide carbidopa ) least 28 day prior Baseline Visit If subject receive anticholinergic , monoamine oxidase ( MAO ) B inhibitor , amantadine , he/she must stable dose least 28 day prior Baseline Visit must maintain dose duration study Subject discontinue previous therapy dopamine agonist adequate length treatment , adequate dose , due lack efficacy assess investigator Subject receive therapy 1 follow drug , either concurrently within 28 day prior Baseline Visit : alphamethyl dopa , metoclopramide , reserpine , neuroleptic ( except specific atypical neuroleptic : olanzapine , ziprasidone , aripiprazole , clozapine , quetiapine ) , monoamine oxidaseA ( MAOA ) inhibitor , methylphenidate , amphetamine , dopamine agonist ( DAs ) Subject receive central nervous system ( CNS ) therapy ( eg , sedative , hypnotic , selective serotonin reuptake inhibitor [ SSRIs ] , anxiolytic , sleepmodifying medication ) unless dose stable daily least 28 day prior Baseline Visit likely remain stable duration study Subject evidence impulse control disorder accord modify Minnesota Impulsive Disorders Interview Screening Visit ( Visit 1 ) , confirm positive structured clinical interview</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
	<keyword>Non-motor symptom</keyword>
</DOC>